tirzepatide injection vs semaglutide for weight loss Troubling Findings in Study of

For instance, in September 2025, Novo Nordisk announced that the Phase 3 OASIS 4 trial demonstrated once-daily oral semaglutide 25 mg produced significantly greater weight loss than placebo in adults with overweight or obesity, supporting the advancement of next-generation oral GLP-1 therapies as a convenient alternative to injectable treatments

PubMed Minder EI, et al

The committee concluded that there is not enough evidence to show the drugs directly cause these symptoms, but noted the complex interplay between mental illness and chronic endocrine disorders, as per The Guardian

C.CalmonA

10.1194/jlr.R067629 154 SchurrA

Arellano-Orden E, Calero Acua C, Snchez-Lpez V, et al